ArticleBMC cancer2022
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 43 citations in OpenAlex.
- Facile Synthesis of Indole-, Pyrazole-, and Indazole-Pyrrolidine Hybrids as Novel Chiral Heterocyclic Building Blocks.Molecules (Basel, Switzerland) · 2026Article
- Synthesis and Characterization of New Functionalized Pyrimidine (Hetero)Cyclic Molecular Hybrids as Chiral Heterocyclic Amino Acid Derivatives.Molecules (Basel, Switzerland) · 2026Article
- Article
- Case Report: Dramatic response to amivantamab plus chemotherapy in EGFR G719A-mutant lung adenocarcinoma with liver and peritoneal metastases.Frontiers in oncology · 2026Article
- The relationship between genetic mutations and organ metastasis in non-small cell lung cancer.Therapeutic advances in medical oncology · 2026Review
- Article
- Plasma-Based Genomic Features Influencing Outcomes of T790M-Positive Non-Small Cell Lung Cancer Receiving Osimertinib.Cancer medicine · 2025Article
- Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy.Advances in therapy · 2025Observational
- FDA approval of Amivantamab-Vmjw in combination with carboplatin and pemetrexed for EGFR-mutated NSCLC: a new therapeutic milestone.Annals of medicine and surgery (2012) · 2025Article
- Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases.Current issues in molecular biology · 2024Article
- Article
- What enlightenment has the development of lung cancer bone metastasis brought in the last 22 years.World journal of clinical oncology · 2024Article
- Article
- Assessing EGFR-mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy.Cancer medicine · 2024Article
- A common molecular and cellular pathway in developing Alzheimer and cancer.Biochemistry and biophysics reports · 2024Review
- Article
- Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR Mutations.JTO clinical and research reports · 2024Article
- A destabilizing Y891D mutation in activated EGFR impairs sensitivity to kinase inhibition.NPJ precision oncology · 2024Article
- Determination of osimertinib concentration in rat plasma and lung/brain tissues.American journal of translational research · 2024Article
- Femoral bone metastasis is a poor prognostic factor in EGFR-TKIs-treated patients withTherapeutic advances in medical oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsimertinib-the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib demonstrated central nervous system activity in patients with brain metastasis; however, its efficacy against other distant metastatic organs, including bone and liver, remains unclear. Therefore, we retrospectively analyzed the clinical efficacy of osimertinib in these patients in comparison to other EGFR-TKIs.
methodsClinical data of patients with advanced NSCLC receiving gefitinib/erlotinib (n = 183), afatinib (n = 55), or osimertinib (n = 150) at five medical institutions were retrospectively assessed for progression-free survival (PFS), overall survival (OS), and best overall response rate (ORR).
resultsIn univariate and multivariate analyses, most distant metastases, including the brain and bone, were unrelated to the therapeutic efficacy of osimertinib, although liver metastasis and L858R mutation were independently associated with shorter PFS. PFS and OS in patients with liver metastases were significantly shorter than those in patients without liver metastases (PFS: 7.4 vs. 19.7 months, OS: 12.1 months vs. not reached, respectively). Osimertinib provided significantly longer PFS in patients with brain or bone metastasis and exon 19 deletion than the other EGFR-TKIs. The PFS of patients with liver metastases was not significantly different among the three EGFR-TKI groups. Furthermore, the ORR of osimertinib in patients with liver metastases was significantly attenuated, and the effectiveness was similar to 1
conclusionOsimertinib provided better clinical benefits than 1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.